GlassScriptPhysician profile
Issam A Daya
NPI 1750424552
$3,317.05
in general payments reported to CMS, 2019-2025
32 companies · $409 in 2025
The $409 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $624 · 2021: $536 · 2022: $441 · 2023: $516 · 2024: $347 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.76 |
| Education | $210.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $481.95 | 2022-2024 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $383.72 | 2019-2025 | Slynd, Tyblume |
| Therapeuticsmd, INC. | $364.56 | 2019-2022 | |
| Abbvie INC. | $260.65 | 2019-2022 | |
| Sage Therapeutics, LLC | $246.43 | 2024-2025 | Zurzuvae |
| Avion Pharmaceuticals | $200.53 | 2019-2021 | |
| Millicent US INC | $191.16 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Pfizer INC. | $174.14 | 2019-2023 | |
| Myovant Sciences INC. | $172.82 | 2021-2022 | |
| Evofem Biosciences, INC. | $106.03 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $95.63 | 2021-2025 | |
| Coopersurgical, INC. | $74.15 | 2019-2024 | Paragard T 380a |
| Lupin INC. | $61.04 | 2019-2020 | |
| Daiichi Sankyo INC. | $59.92 | 2021 | |
| Supernus Pharmaceuticals, INC. | $56.68 | 2025 | Qelbree |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $49.36 | 2020-2021 | |
| Aspira Women'S Health INC | $41.26 | 2020-2023 | Ova1 |
| Sumitomo Pharma America, INC. | $37.78 | 2023 | Myfembree |
| Allergan, INC. | $36.57 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $35.88 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.49 | 2019-2020 | |
| Scynexis, INC. | $31.47 | 2021 | |
| Shield Therapeutics INC | $24.73 | 2023 | Accrufer |
| Organon LLC | $21.41 | 2022 | |
| Exact Sciences Corporation | $20.60 | 2025 | Cologuard Collection Kit |
| Channel Medsystems, INC. | $19.08 | 2024 | |
| Amgen INC. | $12.83 | 2019 | |
| Horizon Therapeutics Plc | $12.24 | 2021 | |
| Meditrina | $10.94 | 2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Issam Daya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.